Jefferies Financial Group Inc. Acquires Shares of 51,400 Beta Bionics, Inc. $BBNX

Jefferies Financial Group Inc. acquired a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,400 shares of the company’s stock, valued at approximately $1,566,000. Jefferies Financial Group Inc. owned 0.12% of Beta Bionics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of BBNX. GPS Wealth Strategies Group LLC grew its holdings in Beta Bionics by 45.0% during the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Strs Ohio purchased a new stake in Beta Bionics during the first quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the last quarter. Legal & General Group Plc lifted its holdings in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after purchasing an additional 1,863 shares during the last quarter.

Beta Bionics Stock Down 0.8%

BBNX stock opened at $11.63 on Thursday. The stock has a 50-day simple moving average of $10.66 and a two-hundred day simple moving average of $17.83. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The firm has a market capitalization of $518.23 million, a PE ratio of -7.70 and a beta of 3.29.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The firm had revenue of $27.63 million during the quarter. On average, equities research analysts anticipate that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on BBNX. Robert W. Baird dropped their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Lake Street Capital set a $20.00 target price on shares of Beta Bionics in a report on Wednesday, February 18th. Finally, UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.73.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.